In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Balkanized State Of Molecular Diagnostics Reimbursement

Executive Summary

Recent moves by CMS have left up in the air an innovative program that gives labs a clearer opportunity to demonstrate clinical utility and test value. It’s therefore unclear whether companies and their backers should expect any greater certainty over the ability to command premium prices for high-value diagnostic tests.

Advertisement

Related Content

Systems Biology Goes Commercial As Integrated Diagnostics Launches Lung Nodule Test
Device Trends To Watch In 2013
Veracyte: How To Build A Molecular Cytology Company
Trends In Diagnostics – 2012
Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics
Genetic Tests As Physician Fees Or Lab Fees? CMS Asks For Input
Veracyte Meets New Medicare Coverage Mandate For Molecular Dx
Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls
With Genetic Test Codes Developed, CMS Undecided On How To Pay For Them

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel